These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1. Wang Z; Chen CC; Chen W Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808 [TBL] [Abstract][Full Text] [Related]
6. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Hu Y; Chen Y; Douglas L; Li S Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703 [TBL] [Abstract][Full Text] [Related]
7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
8. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417 [TBL] [Abstract][Full Text] [Related]
9. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model. Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649 [TBL] [Abstract][Full Text] [Related]
10. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Lounnas N; Frelin C; Gonthier N; Colosetti P; Sirvent A; Cassuto JP; Berthier F; Sirvent N; Rousselot P; Dreano M; Peyron JF; Imbert V Int J Cancer; 2009 Jul; 125(2):308-17. PubMed ID: 19378338 [TBL] [Abstract][Full Text] [Related]
12. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Gross AW; Ren R Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343 [TBL] [Abstract][Full Text] [Related]
13. Leukemia stem cells: the root of chronic myeloid leukemia. Zhou H; Xu R Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979 [TBL] [Abstract][Full Text] [Related]
14. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
15. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100 [TBL] [Abstract][Full Text] [Related]
16. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. Huang WC; Tsai CC; Chen CL; Chen TY; Chen YP; Lin YS; Lu PJ; Lin CM; Wang SH; Tsao CW; Wang CY; Cheng YL; Hsieh CY; Tseng PC; Lin CF FASEB J; 2011 Oct; 25(10):3661-73. PubMed ID: 21705667 [TBL] [Abstract][Full Text] [Related]
17. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174 [TBL] [Abstract][Full Text] [Related]